drugset / Trial / NCT06981988
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.
Timeline
- Start
- 2025-06
- Primary completion
- 2025-08
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |